EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study

Ryota Saito, Shunichi Sugawara, Ryo Ko, Koichi Azuma, Ryo Morita, Makoto Maemondo, Satoshi Oizumi, Kazuhisa Takahashi, Hiroshi Kagamu, Yukari Tsubata, Masahiro Seike, Toshiaki Kikuchi und 6 weitere

European Journal of Cancer · 2023-05 · 185 · 83-93

DOI: 10.1016/j.ejca.2023.02.023 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2023-05. Verfasst von Ryota Saito und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tohoku University, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPemetrexedPlatinumAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsMutationAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

EGFR mutationNon-small cell lung cancerOsimertinibPemetrexedPlatinum-based chemotherapy

Substanzen

PemetrexedPlatinumErbB ReceptorsosimertinibAcrylamidesAniline CompoundsIndolesPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Tohoku University, Sendai, Japan.
  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan.
  • Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.

Zitieren

APA

Saito, R., Sugawara, S., Ko, R., Azuma, K., Morita, R., Maemondo, M., Oizumi, S., Takahashi, K., Kagamu, H., Tsubata, Y., Seike, M., Kikuchi, T., Okamoto, I., Satoshi, M., Asahina, H., Tanaka, K., Sugio, K., & Kobayashi, K. (2023). Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer, 185, 83-93. https://doi.org/10.1016/j.ejca.2023.02.023

Vancouver

Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer. 2023;185:83-93. doi:10.1016/j.ejca.2023.02.023

BibTeX
@article{Saito2023,
  author = {Saito, Ryota and Sugawara, Shunichi and Ko, Ryo and Azuma, Koichi and Morita, Ryo and Maemondo, Makoto and Oizumi, Satoshi and Takahashi, Kazuhisa and Kagamu, Hiroshi and Tsubata, Yukari and Seike, Masahiro and Kikuchi, Toshiaki and Okamoto, Isamu and Satoshi, Morita and Asahina, Hajime and Tanaka, Kentaro and Sugio, Kenji and Kobayashi, Kunihiko},
  title = {Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study},
  journal = {European Journal of Cancer},
  year = {2023},
  volume = {185},
  pages = {83--93},
  doi = {10.1016/j.ejca.2023.02.023}
}
Kostenlos starten →